Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$4,819 Mln
P/E Ratio
--
P/B Ratio
60.31
Industry P/E
--
Debt to Equity
-5.14
ROE
-5.72 %
ROCE
-126.84 %
Div. Yield
0 %
Book Value
--
EPS
-5.26
CFO
$-1,144.29 Mln
EBITDA
$-1,391.98 Mln
Net Profit
$-1,754.13 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Cytokinetics Inc (CYTK)
| -14.05 | -13.18 | -20.33 | -39.49 | 4.03 | 20.86 | 18.75 |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Cytokinetics Inc (CYTK)
| -43.39 | 82.21 | 0.53 | 119.35 | 95.85 | 67.88 | -22.35 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.43 | 10,315.11 | 21.27 | 23.13 | |
| 298.55 | 8,705.27 | 22.77 | 66.44 | |
| 27.22 | 10,589.59 | -- | -28.77 | |
| 106.73 | 10,559.67 | 32.44 | 14.16 |
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops... small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase II clinical trial; and aficamten, a novel, oral, small molecule cardiac myosin inhibitor which is in Phase III clinical trial discovered for the treatment of hypertrophic cardiomyopathy. It has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California. Read more
CEO, President, Principal Financial Officer & Director
Mr. Robert I. Blum
CEO, President, Principal Financial Officer & Director
Mr. Robert I. Blum
Headquarters
South San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Cytokinetics Inc (CYTK) stood at $ 1,402 Mln as on 31-Dec-24
The share price of Cytokinetics Inc (CYTK) is $40.43 (NASDAQ) as of 25-Apr-2025 16:00 EDT. Cytokinetics Inc (CYTK) has given a return of 4.03% in the last 3 years.
Cytokinetics Inc (CYTK) has a market capitalisation of $ 4,819 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Cytokinetics Inc (CYTK) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Cytokinetics Inc (CYTK) and enter the required number of quantities and click on buy to purchase the shares of Cytokinetics Inc (CYTK).
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase II clinical trial; and aficamten, a novel, oral, small molecule cardiac myosin inhibitor which is in Phase III clinical trial discovered for the treatment of hypertrophic cardiomyopathy. It has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
The CEO & director of Mr. Robert I. Blum. is Cytokinetics Inc (CYTK), and CFO & Sr. VP is Mr. Robert I. Blum.
There is no promoter pledging in Cytokinetics Inc (CYTK).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Cytokinetics Inc (CYTK) | Ratios |
|---|---|
|
Return on equity(%)
|
226
|
|
Operating margin(%)
|
-2722.82
|
|
Net Margin(%)
|
-3191.11
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Cytokinetics Inc (CYTK) was $0 Mln.
$0.10
(
